Everolimus-Eluting Stents Superior for T2D

ACC Conference Reporter

TCT 2015 | SAN FRANCISCO — The everolimus-eluting Xience stent is a better choice for treating coronary artery disease in patients with type 2 diabetes than the paclitaxel-eluting TAXUS stent. Read More >>>

Keywords: Transcatheter Cardiovascular Therapeutics


< Back to Listings